https://www.selleckchem.com/products/tasquinimod.html 05). 38% of the variance of QoL was predicted by perceived body image and income of the family. 34% of the variance of psychosocial adjustment was predicted by perceived body image (p<0.05). Adolescents suffering phantom limb pain were seen to have lower QoL scores (p<0.05). BID is an important predictor of psychosocial adjustment and QoL in adolescent amputees. Therefore, a prosthesis that ensures the integrity of the body image should be fitted at an as early age as possible before the onset of body image disorder. BID is an important predictor of psychosocial adjustment and QoL in adolescent amputees. Therefore, a prosthesis that ensures the integrity of the body image should be fitted at an as early age as possible before the onset of body image disorder. Shenyankangfu Tablet (SYKFT) is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney disease. This trial compared the efficacy and safety of SYKFT, for the control of proteinuria in primary glomerulonephritis patients, against the standard drug, losartan potassium. This was a multicenter, double-blind, randomized, controlled clinical trial. Primary glomerulonephritis patients, aged 18-70years, with blood pressure≤140/90mmHg, estimated glomerular filtration rate (eGFR)≥45mL/min per 1.73m , and 24-hour proteinuria level of 0.5-3.0g, were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups SYKFT, losartan potassium 50mg or 100mg, SYKFT plus losartan potassium 50mg or 100mg. The primary outcome was change in the 24-hour proteinuria level, after 48weeks of treatment. A total of 735 participants were enrolled. The percent decline of urine protein quantification in the SYKFT group after 48weeks was 8te of decrease in the eGFR. SYKFT plus losartan potassium therapy decreased proteinuria more than losartan potassium therapy alone. NCT02063100 on ClinicalTrials.g